Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: The case of anamorelin

Stefan D Anker, Andrew J S Coats, John E. Morley

    Research output: Contribution to journalEditorialOtherpeer-review

    24 Citations (Scopus)

    Abstract

    A major component of the cancer anorexia-cachexia syndrome is a decline in food intake. Up until now none of the drugs that improve appetite also improve skeletal muscle. Recent studies have suggested that the oral ghrelin-analog, anamorelin, increased food intake and muscle mass. Unfortunately, it does not increase muscle power. Its regulatory future is uncertain, although it has important clinical effects.

    Original languageEnglish
    Pages (from-to)275-277
    Number of pages3
    JournalJournal of Cachexia, Sarcopenia and Muscle
    Volume6
    Issue number4
    DOIs
    Publication statusPublished - 2015

    Cite this